Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Leerink Partnrs lowered their FY2024 earnings estimates for shares of Voyager Therapeutics in a note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst L. Nsongo now anticipates that the company will post earnings per share of ($0.66) for the year, down from their previous estimate of ($0.44). Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($1.27) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics' Q4 2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($1.16) EPS and FY2028 earnings at ($0.45) EPS.
Several other research analysts have also recently weighed in on VYGR. Canaccord Genuity Group reaffirmed a "buy" rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday. Wedbush decreased their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating for the company in a research note on Wednesday, August 7th. StockNews.com downgraded Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Sunday, November 10th. Leerink Partners started coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an "outperform" rating and a $15.00 price target on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Voyager Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.00.
Read Our Latest Research Report on VYGR
Voyager Therapeutics Price Performance
VYGR stock traded down $0.58 during trading hours on Friday, reaching $5.64. 795,762 shares of the stock were exchanged, compared to its average volume of 643,205. The firm's 50-day moving average is $6.63 and its 200-day moving average is $7.52. Voyager Therapeutics has a 12 month low of $5.59 and a 12 month high of $11.72. The company has a market cap of $307.55 million, a price-to-earnings ratio of 8.11 and a beta of 0.89.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in VYGR. Ameritas Investment Partners Inc. grew its position in shares of Voyager Therapeutics by 49.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company's stock worth $37,000 after purchasing an additional 1,300 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company's stock worth $102,000 after acquiring an additional 1,630 shares during the period. SummerHaven Investment Management LLC lifted its holdings in shares of Voyager Therapeutics by 2.5% during the 2nd quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company's stock worth $611,000 after acquiring an additional 1,921 shares during the period. Hunter Perkins Capital Management LLC boosted its holdings in shares of Voyager Therapeutics by 3.3% in the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company's stock valued at $375,000 after purchasing an additional 2,025 shares in the last quarter. Finally, Empowered Funds LLC raised its holdings in shares of Voyager Therapeutics by 5.4% during the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company's stock worth $262,000 after buying an additional 2,278 shares in the last quarter. Institutional investors own 48.03% of the company's stock.
Insider Activity at Voyager Therapeutics
In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business's stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now directly owns 86,001 shares in the company, valued at $500,525.82. The trade was a 6.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.53% of the stock is owned by company insiders.
About Voyager Therapeutics
(
Get Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Read More
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
